It was viewing the Arthritis Foundation / FDA summit videos that really opened my eyes to the determination within the FDA to find and approve safe and effective therapeutics for OA, and the sheer size of that challenge up until relatively recent scientific understanding of the disease and the MOA of various candidate drugs, as well as the obviously dire risks if they got it wrong in any way. I challenge anyone to watch those recordings and come away genuinely thinking the FDA representatives are just pretending and only want to protect 'big-NSAID' or whatever. The riskiest issues for PAR shareholders are much closer to home I fear.
The Miracle of iPPS on MPS -Revisited, page-13
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |